Lucia Festino

1.8k total citations · 1 hit paper
39 papers, 1.2k citations indexed

About

Lucia Festino is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Lucia Festino has authored 39 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 23 papers in Molecular Biology and 12 papers in Immunology. Recurrent topics in Lucia Festino's work include Cancer Immunotherapy and Biomarkers (24 papers), Melanoma and MAPK Pathways (20 papers) and CAR-T cell therapy research (13 papers). Lucia Festino is often cited by papers focused on Cancer Immunotherapy and Biomarkers (24 papers), Melanoma and MAPK Pathways (20 papers) and CAR-T cell therapy research (13 papers). Lucia Festino collaborates with scholars based in Italy, United States and Malaysia. Lucia Festino's co-authors include Paolo A. Ascierto, Vito Vanella, Ester Simeone, Antonio Maria Grimaldi, Diana Giannarelli, Corrado Caracò, Gabriele Madonna, Mariaelena Capone, Giuseppe Palmieri and Miriam Paone and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Lancet Oncology.

In The Last Decade

Lucia Festino

39 papers receiving 1.2k citations

Hit Papers

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived... 2018 2026 2020 2023 2018 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
    2018 351 citations Mariaelena Capone, Diana Giannarelli et al. Journal for ImmunoTherapy of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lucia Festino Italy 18 880 375 368 190 109 39 1.2k
Vito Vanella Italy 16 709 0.8× 267 0.7× 328 0.9× 145 0.8× 87 0.8× 34 997
Miren Zuazo Spain 17 1.0k 1.2× 760 2.0× 296 0.8× 195 1.0× 123 1.1× 27 1.4k
Habib Sadeghirad Australia 7 509 0.6× 298 0.8× 238 0.6× 146 0.8× 82 0.8× 14 837
Anne Montfort France 14 745 0.8× 716 1.9× 293 0.8× 111 0.6× 136 1.2× 19 1.2k
Erin McNamara United States 8 624 0.7× 366 1.0× 336 0.9× 89 0.5× 84 0.8× 18 971
Yavar Shiravand Italy 7 493 0.6× 285 0.8× 214 0.6× 147 0.8× 66 0.6× 9 844
Hong Zheng China 13 569 0.6× 505 1.3× 632 1.7× 118 0.6× 179 1.6× 67 1.4k
Shisuo Du China 18 471 0.5× 291 0.8× 412 1.1× 241 1.3× 212 1.9× 77 1.2k

Countries citing papers authored by Lucia Festino

Since Specialization
Citations

This map shows the geographic impact of Lucia Festino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lucia Festino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lucia Festino more than expected).

Fields of papers citing papers by Lucia Festino

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lucia Festino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lucia Festino. The network helps show where Lucia Festino may publish in the future.

Co-authorship network of co-authors of Lucia Festino

This figure shows the co-authorship network connecting the top 25 collaborators of Lucia Festino. A scholar is included among the top collaborators of Lucia Festino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lucia Festino. Lucia Festino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Granata, Vincenza, Roberta Fusco, Sergio Venanzio Setola, et al.. (2023). Immunotherapy Assessment: A New Paradigm for Radiologists. Diagnostics. 13(2). 302–302. 4 indexed citations
2.
Galati, Domenico, Serena Zanotta, Mariaelena Capone, et al.. (2023). Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients. Journal of Translational Medicine. 21(1). 318–318. 8 indexed citations
3.
Cristinziano, Leonardo, Luca Modestino, Mariaelena Capone, et al.. (2022). PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab. Frontiers in Immunology. 13. 962669–962669. 5 indexed citations
4.
Borzillo, Valentina, Rossella Di Franco, Diana Giannarelli, et al.. (2021). Ipilimumab and Stereotactic Radiosurgery with CyberKnife® System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience. Cancers. 13(8). 1857–1857. 8 indexed citations
5.
Vanella, Vito, et al.. (2021). Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma. Expert Opinion on Emerging Drugs. 26(2). 79–92. 14 indexed citations
6.
Festino, Lucia, et al.. (2021). Dermatologic adverse events associated with targeted therapies for melanoma. Expert Opinion on Drug Safety. 21(3). 385–395. 1 indexed citations
7.
8.
Dimitriou, Florentia, Anne Zaremba, Clara Allayous, et al.. (2021). Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. European Journal of Cancer. 149. 37–48. 17 indexed citations
9.
Guida, Michele, Sabino Strippoli, Milena Maule, et al.. (2021). Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study. ESMO Open. 6(2). 100064–100064. 35 indexed citations
10.
Simeone, Ester, Antonio Maria Grimaldi, Lucia Festino, et al.. (2019). Nivolumab for the treatment of small cell lung cancer. Expert Review of Respiratory Medicine. 14(1). 5–13. 6 indexed citations
11.
Trojaniello, Claudia, Lucia Festino, Vito Vanella, & Paolo A. Ascierto. (2019). Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. Expert Review of Clinical Pharmacology. 12(3). 259–266. 41 indexed citations
12.
Capone, Mariaelena, Diana Giannarelli, Domenico Mallardo, et al.. (2018). Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. Journal for ImmunoTherapy of Cancer. 6(1). 74–74. 351 indexed citations breakdown →
13.
Simeone, Ester, Antonio Maria Grimaldi, Lucia Festino, et al.. (2017). Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. OncoImmunology. 6(3). e1283462–e1283462. 30 indexed citations
14.
Vanella, Vito, Lucia Festino, Martina Strudel, et al.. (2017). PD-L1 inhibitors in the pipeline: Promise and progress. OncoImmunology. 7(1). e1365209–e1365209. 36 indexed citations
15.
Simeone, Ester, Antonio Maria Grimaldi, Lucia Festino, et al.. (2017). Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care. BioDrugs. 31(1). 51–61. 51 indexed citations
16.
Grimaldi, Antonio Maria, Ester Simeone, Lucia Festino, et al.. (2017). MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors. American Journal of Clinical Dermatology. 18(6). 745–754. 98 indexed citations
17.
Festino, Lucia, Gerardo Botti, Paul Lorigan, et al.. (2016). Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. Drugs. 76(9). 925–945. 120 indexed citations
18.
Ascierto, Paolo A., Vito Vanella, Antonio Maria Grimaldi, et al.. (2016). Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial. Cancer Immunology Immunotherapy. 65(11). 1395–1400. 17 indexed citations
19.
Grimaldi, Antonio Maria, Ester Simeone, Lucia Festino, et al.. (2015). Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.. PubMed. 19(107). 455–61. 20 indexed citations
20.
Mozzillo, Nicola, Ester Simeone, Marcello Curvietto, et al.. (2015). Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. OncoImmunology. 4(6). e1008842–e1008842. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vito Vanella Breakdown of academic impact, for papers by Miren Zuazo Breakdown of academic impact, for papers by Habib Sadeghirad Breakdown of academic impact, for papers by Anne Montfort Breakdown of academic impact, for papers by Erin McNamara Breakdown of academic impact, for papers by Yavar Shiravand Breakdown of academic impact, for papers by Hong Zheng Breakdown of academic impact, for papers by Shisuo Du
Rankless by CCL
2026